Amneal Pharmaceuticals (AMRX) Stock May Be Fully Priced Following Its 4.7x Run
Amneal Pharmaceuticals (AMRX) has experienced a significant 4.7x share price increase over the last three years, leading to a valuation that appears expensive compared to industry averages. Despite recent FDA approval for its iohexol injection portfolio, the stock's current P/E ratio of 46.8x is …